Companies
Key Facts
—The move. Natura shares rose more than 5 percent, briefly leading the Ibovespa, after a preliminary second-quarter update.
—The warning. The group guided to net revenue of R$5.1bn to R$5.2bn ($990m-$1bn), down 9 to 10 percent on the year.
—The miss. That fell short of Morgan Stanley’s R$5.6bn estimate and a market consensus near R$5.5bn.
—The upside. Natura still expects its reported margin to improve from the first quarter’s 7.3 percent.
—The context. The stock is up more than 40 percent in 2026, well ahead of the wider market.
Natura shares did something counter-intuitive on Wednesday, jumping more than five percent on a day the cosmetics group warned its sales had fallen harder than expected. Investors looked past the weak top line and fixed instead on the promise of fatter margins.
The Brazilian beauty group issued a preliminary, unaudited snapshot of its second quarter ahead of full results, InfoMoney reported. It flagged a revenue drop steeper than the market had penciled in, yet the stock briefly led Brazil’s benchmark index higher.
A preliminary update like this is a partial picture, shared before the audited numbers are ready. Companies often release one when the headline figures are likely to move the share price, giving the market an early steer.
The Ibovespa is Brazil’s main stock index, tracking the most actively traded companies on the São Paulo exchange. Leading that index, even briefly, signals strong investor interest and marks the stock as one of the day’s best performers by percentage gain.
For a foreign investor, this is a lesson in how expectations work. When a company has already warned of pain, evidence that the pain is easing elsewhere can matter more than another soft sales figure.
Why Natura shares rose on bad news
The reason lies in profitability, not sales. Alongside the weaker revenue, Natura said it expects its reported margin to widen compared with the first quarter, when it stood at just over seven percent.
Margin here means the share of each real of revenue that remains as profit after costs are paid. A wider margin signals the company is either charging more, spending less, or both.
In a turnaround story, that kind of cost discipline is exactly what the market wants to see. It suggests the business can protect earnings even while sales are still under pressure.
That margin story is what analysts said lifted the mood. The company has been cutting costs and reshaping its operations, and any sign those savings are reaching the bottom line reassures the market.
The revenue miss itself was real, however. Natura guided to consolidated net revenue between about five point one and five point two billion reais, a fall of nine to ten percent on the year and below every major estimate.
That range came in under Morgan Stanley’s forecast of about five point six billion reais. It also trailed a broader market consensus near five point five billion, leaving the shortfall clear to see.
Consolidated revenue means the combined sales of all the brands and businesses Natura controls, rolled up into a single figure. Net revenue strips out returns, discounts and certain taxes, giving a cleaner picture of what the company actually earned from customers.
What is dragging on sales
The weakness is centred at home. Natura blamed a cooler consumer environment in Brazil, where household spending on beauty has softened as families feel the squeeze.
Beauty and personal care are often among the first things shoppers trim when budgets tighten. That makes a company like Natura sensitive to shifts in how confident and how flush its customers feel.
Internal disruption added to the drag. The company cited the closure of a factory, a reworking of its franchise contracts and a temporary tax mismatch as further weights on the quarter.
Those are the kind of self-inflicted, one-off costs that come with reshaping a business. They can hurt a single quarter while, in theory, setting up a leaner operation later.
Those headwinds outweighed brighter spots abroad. Growth in the group’s Spanish-speaking markets was not enough to offset the shortfall at home, leaving overall revenue lower.
The share price sits in a striking place given all this. Despite the soft quarter, Natura stock is up more than forty percent so far in 2026, far outpacing the wider Brazilian market.
That kind of rally suggests investors are pricing in a recovery that has not yet shown up in the revenue line. The question is whether margin gains alone can justify the valuation if sales remain under pressure for longer than expected.
Part of that optimism is about ownership. The private-equity firm Advent International has built a stake and is set to nominate directors, a shift the market sees as a boost to governance and discipline.
Private-equity involvement often signals a focus on operational efficiency and financial performance, as these firms typically seek to improve profitability before eventually exiting. Director nominations give the investor formal influence over strategy and oversight.
Some big banks share the upbeat view. JPMorgan recently upgraded the stock to overweight with a higher price target, betting that cost cuts and cash generation will reward patient shareholders.
An overweight rating means the analyst expects the stock to outperform its sector or benchmark over the coming months. It is a buy recommendation, though not the strongest tier at most banks.
Not everyone is convinced by the rally. Other analysts warn that the weak Brazilian consumer could force further cuts to earnings forecasts before the promised recovery arrives in the second half.
The wider strategy hinges on a relaunch. Natura is rolling out a revamped version of its Avon brand, starting in Brazil, in a bid to revive a franchise that has long weighed on group sales.
Whether that relaunch can reverse years of decline in a tough consumer environment remains an open question. So too does the timing: will margin improvements buy enough goodwill to keep investors patient if the top line stays soft through the rest of the year?
Live Company IntelligenceNatura Cosmeticos S.A. — the full investor dossier
Valuation & profitability
Price & risk
$7.1352-wk high
$11.15
Revenue trend · 6y
Ownership
Dividend
Frequently Asked Questions
Why did Natura shares rise despite weaker revenue?
Because the company had already warned of a tough first half, so the soft revenue was largely expected, while the promise of an improving margin was the fresh, positive signal. Investors judged that costs are being brought under control, which matters more for a turnaround stock than one more quarter of falling sales.
What is Natura and why does it matter?
Natura is one of Latin America’s largest cosmetics groups, a Brazilian direct-sales giant that also owns the premium brand Aesop. Its recovery is closely watched because it is a bellwether for Brazilian consumer demand and a favourite of both local and foreign investors.
When is the recovery expected?
Management has signalled that results should begin to recover in the second half of 2026, as cost cuts and a new operating model feed through. Analysts remain divided, with some warning of further downgrades and others betting the weakness marks a buying opportunity.
This article was produced by The Rio Times’ automated newsroom system. How we use AI · Report an error
LatAm Markets: Live Signals → — real-time movers, turnover leaders and FX across Latin America.
Read More from The Rio Times